ReviewDrug design, development and therapy2014
Transdermal testosterone replacement therapy in men.
Review in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections: A Phase IV, Prospective, Randomized, Non-Blinded, Multi-Institutional Study
Randomized Control Trial of Long Acting Subcutaneous Testosterone Pellets for Hypogonadism: Testopel ® vs. Generic Testosterone Pellets.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review.Current cardiology reviews · 2021Pooled it
- Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Guideline
- What anabolic-androgenic steroids reveal about the limits of current harm reduction models.Addiction (Abingdon, England) · 2026Article
- Alternatives to serum testing for transdermal testosterone monitoring: a review of clinical data and correlation with clinical response.Frontiers in reproductive health · 2026Article
- Anabolic steroid consumption among gym-goers in Amman: knowledge, attitudes, and behaviors.Frontiers in sports and active living · 2024Article
- Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.Journal of medical case reports · 2022Article
- Review
- Medicinal Use of Testosterone and Related Steroids Revisited.Molecules (Basel, Switzerland) · 2021Review
- Effects of pharmacologically induced Leydig cell testosterone production on intratesticular testosterone and spermatogenesis†.Biology of reproduction · 2020Article
- A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys.Pharmacology research & perspectives · 2020Article
- Anabolic-androgenic steroids and cardiovascular risk.Chinese medical journal · 2019Review
- Body composition changes with testosterone replacement therapy following spinal cord injury and aging: A mini review.The journal of spinal cord medicine · 2018Review
- Novel Therapy for Male Hypogonadism.Current urology reports · 2018Review
- New light on an old vitamin: The role of the sunshine vitamin D in chronic disease.Reviews in endocrine & metabolic disorders · 2017Article
- Effects of Elevated β-Estradiol Levels on the Functional Morphology of the Testis - New Insights.Scientific reports · 2017Article
- Cardiovascular disease in transgendered people: A review of the literature and discussion of risk.JRSM cardiovascular diseaseReview
- Physicians' attitudes towards androgen replacement therapy for male and female sexual dysfunction.International journal of impotence researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen deficiency syndrome in men is a frequently diagnosed condition associated with clinical symptoms including fatigue, decreased libido, erectile dysfunction, and metabolic syndrome. Serum testosterone concentrations decline steadily with age. The prevalence of androgen deficiency syndrome in men varies depending on the age group, known and unknown comorbidities, and the respective study group. Reported prevalence rates may be underestimated, as not every man with symptoms of androgen deficiency seeks treatment. Additionally, men reporting symptoms of androgen deficiency may not be correctly diagnosed due to the vagueness of the symptom quality. The treatment of androgen deficiency syndrome or male hypogonadism may sometimes be difficult due to various reasons. There is no consensus as to when to start treating a respective man or with regards to the best treatment option for an individual patient. There is also lack of familiarity with treatment options among general practitioners. The formulations currently available on the market are generally expensive and dose adjustment protocols for each differ. All these factors add to the complexity of testosterone replacement therapy. In this article we will discuss the general indications of transdermal testosterone replacement therapy, available formulations, dosage, application sites, and recommended titration schedule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.